Takahashi T, Okamoto T, Yokota I, et al. - Among pediatric patients with refractory nephrotic syndrome (NS), researchers investigated the impact of a periodically repeated rituximab (RTX) treatment on quality of life (QOL). Through a two‐year RTX treatment protocol, QOL was systematically examined in 22 patients, as well as parents’ perceptions of their child’s QOL were noted. RTX infusion was given 4 times at 6‐month intervals, followed by mizoribine use with early discontinuation of calcineurin inhibitors. Findings in these patients with refractory NS revealed a significant improvement of QOL in relation to this treatment protocol. Although consideration should be given to the risk of the RTX treatment, the treatment is beneficial for refractory NS cases.